These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 30267996)

  • 1. Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease.
    Lotan I; Hellmann MA; Benninger F; Stiebel-Kalish H; Steiner I
    J Neuroimmunol; 2018 Nov; 324():115-118. PubMed ID: 30267996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of anti-MOG antibody testing in a Danish cohort.
    Papp V; Langkilde AR; Blinkenberg M; Schreiber K; Jensen PEH; Sellebjerg F
    Mult Scler Relat Disord; 2018 Nov; 26():61-67. PubMed ID: 30227311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and radiologic approach to 'typical' versus antibody-related optic neuritis.
    Caron-Cantin M; Cestari DM; Fortin E
    Curr Opin Ophthalmol; 2019 Nov; 30(6):412-417. PubMed ID: 31503075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profile, imaging features and short term visual outcomes of Indian optic neuritis patients with and without seromarkers for myelin oligodendrocyte glycoprotein and neuromyelitis optica.
    Ambika S; Durgapriyadarshini S; Padmalakshmi K; Noronha V; Arjundas D
    Indian J Ophthalmol; 2022 Jan; 70(1):194-200. PubMed ID: 34937238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein.
    Koç S; Şen S; Terzi Y; Kızılay F; Demir S; Bekar Aksoy D; Kurtuluş F; Bilge N; Idilman E; Uzunköprü C; Güngör S; Çilingir V; Ethemoğlu Ö; Boz C; Gümüş H; Kılıç AK; Kısabay A; Bir LS; Turan ÖF; Soysal A; Köseoğlu M; Tekgöl Uzuner G; Bayındır H; Canbaz Kabay S; Çam M; Yayla V; Tan H; Özcan A; Taşkapıoğlu Ö; Korkmaz M; Tamam Y; İnanç Y; Efendi H; Kotan D; Yetkin MF; Bilgiç AB; Saçmacı H; Demirci S; Çelik Y; Poyraz T; Terzi M
    Balkan Med J; 2024 Jul; 41(4):272-279. PubMed ID: 38828767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
    Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
    Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease.
    Rosenthal JF; Hoffman BM; Tyor WR
    J Investig Med; 2020 Feb; 68(2):321-330. PubMed ID: 31582425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
    Ramanathan S; Prelog K; Barnes EH; Tantsis EM; Reddel SW; Henderson AP; Vucic S; Gorman MP; Benson LA; Alper G; Riney CJ; Barnett M; Parratt JD; Hardy TA; Leventer RJ; Merheb V; Nosadini M; Fung VS; Brilot F; Dale RC
    Mult Scler; 2016 Apr; 22(4):470-82. PubMed ID: 26163068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OMG: MS, NMOSD, and MOG.
    Lewis SL
    Continuum (Minneap Minn); 2019 Jun; 25(3):594-595. PubMed ID: 31162306
    [No Abstract]   [Full Text] [Related]  

  • 19. [Anti-MOG antibody in different types of immune-mediated optic neuritis].
    Kong XY; Peng JT; Liu LJ; Yan R; Zhang XJ
    Zhonghua Yan Ke Za Zhi; 2012 Dec; 48(12):1069-72. PubMed ID: 23336409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.